Navigation Links
Biomarkers Market to Grow at a CAGR of 18.5% to 2018 in a New Research Report at

Dallas, Texas (PRWEB) September 29, 2013

A biomarker is an identifiable and measurable characteristic, which identifies the severity and/or occurrence of a specific disease. It has major applications in the discovery and development of novel therapeutic drugs. The global biomarkers market shows a high growth potential and accounts for $17.5 billion in 2013. It is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018.

Advancements in discovery technologies, high demand from the indications of various diseases, increasing partnerships and collaborations to boost biomarker research activities, increase in government and private sector investments and funds for biomarker discovery, FDA support for biomarker development, and increasing utility of biomarkers in patient stratification and drug development process are the major drivers slated to propel the growth of this market. However, a few pivotal factors such as the high capital investment and low benefit-cost ratio, cumbersome biomarker validation procedure, and difficulty in sample collection and its storage are expected to hamper the growth of this market.

Complete report available @ .

The global market has been segmented into discovery technologies, services, applications, and disease indications. The biomarker discovery technology market has been further segmented into omics technology, imaging technology, and bioinformatics. The omics technology segment accounts for the largest share in this market, primarily due to the increase in adoption of proteomics and genomics technologies across the globe.

In addition, the biomarker services (sample preparation, assay development, and biomarker validation and testing) and applications (drug discovery and formulation, and development of molecular diagnostics and personalized medicine) market have also been illustrated in the report. Drug discovery and development segment holds the largest share of biomarker applications market. This is attributed to the potential of biomarkers to reduce the time span of clinical trials, which ultimately decreases the overall cost of the entire drug discovery and development process.

On the basis of type of disease, the global biomarkers market is further classified as oncology, cardiology, neurology, and other diseases (HIV, renal disorders, diabetes, arthritis, and tuberculosis). Oncology biomarkers market accounts for the lion’s share of the biomarker disease indication market and further this market is forecast to grow at the highest growth rate in the next five years. Increasing need for the early diagnosis of tumor cells is the major factor stimulating the growth of oncology market. Oncology biomarkers enhance the screening and early detection of cancer as well as facilitate the high-speed, non-invasive cancer diagnosis procedure.

The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.)

Scope of the Report
This research report categorizes the global biomarkers market on the basis of discovery technology, services, applications, and disease indications. These markets are broken down into segments and sub-segments, providing value analysis for 2011, 2012, and 2013 as well as forecast up to 2018. Each market is comprehensively analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World), to provide in-depth information on the global scenario.

Majors points of table of content
10 Company Profiles
10.1 Abbott Laboratories
10.2 Abcodia Ltd
10.3 Affymetrix Inc
10.4 Agilent Technologies Inc
10.5 Amgen Inc
10.6 Astrazeneca Plc
10.7 Augurex Life Sciences Corp
10.8 Aushon Biosystems Inc
10.9 Bayer Ag
10.11 Bgi
10.12 Biocrates Life Sciences Ag
10.13 Biomarkers Strategies
10.14 Biosystems International
10.15 Bristol-Myers Squibb
10.16 Crescendo Bioscience
10.17 Eisai Co. Ltd.
10.18 Epiontis Gmbh
10.19 Epistem Holdings Plc
10.20 Eurogentec S.A.
10.21 Evotec Ag
10.22 Glaxosmithkline Plc etc.

Purchase a copy of this report @ .

Browse more reports on Information Technology & Telecommunication Market @ .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Explore industry research reports focused on China at .

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biomarkers Market worth $40.8 Billion by 2018
2. Biomarkers: Technological and Commercial Outlook 2013-2023
3. Biomarkers predict time to ovarian cancer recurrence
4. Epigenetic and MicroRNA Biomarkers 2013 Market Report
5. Biomarkers - Technologies, Markets and Companies - Updated 2012 Report
6. Molecular Biomarkers for Cancer Detection and Management
7. Quantitative Analysis of Biomarkers, New Life Science Webinar Hosted by Xtalks
8. Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference
9. MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts
10. Discovery of Circulating Protein Biomarkers by Analysis of the Tissue Secretome, New Life Science Webinar Hosted by Xtalks
11. Central Nervous System (CNS) Biomarkers Market: 2017 Forecast in New Research Report at
Post Your Comments:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):